Prognostic and predictive value of loss of nuclear RAD51 immunoreactivity in resected non-small cell lung cancer patients
- 1 March 2017
- journal article
- research article
- Published by Elsevier in Lung Cancer
- Vol. 105, 31-38
Abstract
No abstract availableKeywords
Funding Information
- European Platform of Thoracic Oncology
- Czech Ministry of Education
- Ministry of Health
- Palacký University
This publication has 33 references indexed in Scilit:
- 2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancerAnnals of Oncology, 2015
- Predictive biomarkers in patients with resected non-small cell lung cancer treated with perioperative chemotherapyEuropean Respiratory Review, 2013
- The BRCA1 ubiquitin ligase and homologous recombination repairFEBS Letters, 2011
- Rad51 overexpression rescues radiation resistance in BRCA2‐defective cancer cellsMolecular Carcinogenesis, 2008
- RAD51 localization and activation following DNA damagePhilosophical Transactions of the Royal Society B: Biological Sciences, 2004
- Homologous recombinational repair of DNA ensures mammalian chromosome stabilityMutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2001
- Chromosome Instability and Defective Recombinational Repair in Knockout Mutants of the Five Rad51 ParalogsMolecular and Cellular Biology, 2001
- Sequestration of Mammalian Rad51-Recombination Protein into MicronucleiJournal of Cell Biology, 1999
- XRCC2 and XRCC3, New Human Rad51-Family Members, Promote Chromosome Stability and Protect against DNA Cross-Links and Other DamagesMolecular Cell, 1998
- Mammalian Rad51 protein: A RecA homologue with pleitropic functionsBiochimie, 1997